Press release
Diffuse Large B-cell Lymphoma Therapeutics: A Leading Driver Behind Rising Prevalence Of Diffuse Large B-Cell Lymphoma To Drive Market Growth Market Expansion in 2025
Diffuse Large B-cell Lymphoma Therapeutics Market
What Will the Diffuse Large B-cell Lymphoma Therapeutics Industry Market Size Be by 2025?
The market for therapeutics used in the treatment of diffuse large B-cell lymphoma has seen significant growth in recent times. The market size is projected to expand from $4.74 billion in 2024 to $5.15 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.5%. The growth observed in the historic period is due to progress in clinical research, regulatory authorization, awareness and diagnosis among patients, and collaborative efforts along with changes in care standards.
What's the Long-Term Growth Forecast for the Diffuse Large B-cell Lymphoma Therapeutics Market Size Through 2029?
Expectations are high for a substantial upswing in the diffusion large B-cell lymphoma therapeutics market in the coming years. It's predicted to expand to $7.05 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 8.2%. This predicted surge over the forecast period can be credited to factors such as breakthroughs in biomarker discovery, improvements in immunotherapy, increasing incidence rates, the global aging population, advancements in healthcare infrastructure, and widened availability of novel drugs. The forecast period is also likely to witness the rise of outpatient treatment settings, collaborative clinical trials, patient-focused caregiving models, progress in diagnostic imaging, and digitalization in the healthcare sector.
View the full report here:
https://www.thebusinessresearchcompany.com/report/diffuse-large-b-cell-lymphoma-therapeutics-global-market-report
What Are the Key Growth Drivers Fueling the Diffuse Large B-cell Lymphoma Therapeutics Market Expansion?
The escalating occurrence of diffuse large B-cell lymphoma (DLBCL) is predicted to drive the expansion of the DLBCL therapeutics market. DLBCL, an intense cancer that originates in the B-cells within the lymphatic system, is known for its rapid and broad-spectrum growth. This cancer belongs to the non-Hodgkin lymphoma (NHL) family. DLBCL therapies aim to enhance results for individuals already suffering from this disease by targeting and controlling the cancer cells. The American Cancer Society, a voluntary health organization based in the US, has projected that by 2023 around 80,550 individuals (44,880 men and 35,670 women) will be diagnosed with NHL, with approximately 20,180 people losing their lives to NHL. Consequently, the rising prevalence of DLBCL is the major propellant for the growth of the DLBCL therapeutics market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10805&type=smp
What Are the Key Trends Driving Diffuse Large B-cell Lymphoma Therapeutics Market Growth?
A prominent trend emerging in the diffuse large B-cell lymphoma therapeutics market is the development of drug therapeutics. Renowned companies in the market are working on creating drugs for treatments to maintain their competitive edge. For example, in June 2022, Bristol-Myers Squibb, a corporation based in the US specializing in pharmaceuticals, particularly in the research and development of drugs, was granted approval by the US FDA for their CAR T Cell Therapy Breyanzi. This therapy is intended to treat patients suffering from various forms of lymphoma, such as diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed, or unresponsive, large B-cell lymphoma. Breyanzi is designed as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, providing potential treatment for a range of patients with high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
How Is the Diffuse Large B-cell Lymphoma Therapeutics Market Segmented?
The diffuse large B-cell lymphoma therapeutics market covered in this report is segmented -
1) By Drug Class: Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs
2) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies
3) By Route of Administration: Oral, Parenteral, Other Routes
4) By End User: Hospitals, Clinics, Other End-Users
Subsegments:
1) By Cisplatin: Injection Formulations, Combination Therapies
2) By Carboplatin: Injection Formulations, Combination Therapies
3) By 5-Fluorouracil: Injection Formulations, Oral Formulations
4) By Docetaxel: Injection Formulations, Combination Therapies
5) By Paclitaxel: Injection Formulations, Combination Therapies
6) By Methotrexate: Injection Formulations, Oral Formulations, Combination Therapies
7) By Other Drugs: Monoclonal Antibodies, Targeted Therapies, Immunotherapies, Experimental Therapies
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10805&type=smp
Which Companies Are Leading the Charge in Diffuse Large B-cell Lymphoma Therapeutics Market Innovation?
Major companies operating in the diffuse large B-cell lymphoma therapeutics market include Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Xencor Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG
Which Regions Are Leading the Global Diffuse Large B-cell Lymphoma Therapeutics Market in Revenue?
North America was the largest region in the global diffuse large B-cell lymphoma therapeutics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diffuse large B-cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10805
This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diffuse Large B-cell Lymphoma Therapeutics: A Leading Driver Behind Rising Prevalence Of Diffuse Large B-Cell Lymphoma To Drive Market Growth Market Expansion in 2025 here
News-ID: 4095403 • Views: …
More Releases from The Business Research Company
Future of Arachidonic Acid Market: Size, Share & Forecasts to 2029
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What Is the Projected Market Size Valuation of the Arachidonic Acid Market by 2025?
The market scope of arachidonic acid has witnessed significant expansion in the recent past. The valuation will inflate from $5.88 billion in 2024 to $6.31 billion in 2025, marking a compound annual growth rate (CAGR) of 7.3%.…
Solvent-Based Inks Market Analysis: $11.09 Billion by 2029 With a CAGR of 4.5%
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
Solvent-Based Inks Market Value Projection: How Much Will the Market Size by 2025?
In the last few years, there has been a consistent expansion in the solvent-based inks market size. The market, which was worth $8.9 billion in 2024, is projected to escalate to $9.28 billion in 2025 at a compound…
Phosgene Market on Path to Hit $6.25 Billion by 2029 at 5.2% CAGR
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Phosgene Market Outlook: What Size And CAGR Are Anticipated By 2025?
The size of the phosgene market has experienced substantial growth recently. It is anticipated to expand from $4.84 billion in 2024 to $5.1 billion in 2025, increasing at a compound annual growth rate (CAGR) of 5.5%. The rise experienced…
Methylene Diphenyl Diisocyanate (MDI)-Based Polyurethane Market to Record 5.1% C …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Methylene Diphenyl Diisocyanate (MDI)-Based Polyurethane Market Outlook: How is the Market Expected to Grow by 2025?
The market size of methylene diphenyl diisocyanate (MDI)-based polyurethane has been progressively increasing over the recent years. It's set to expand from a worth of $20.5 billion in 2024 to an estimated $21.21 billion…
More Releases for Therapeutics
Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight | …
Adrenomyeloneuropathy emerging therapies are expected to boost the Adrenomyeloneuropathy Market in the upcoming years.
DelveInsight has launched a new report on "Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover about the Adrenomyeloneuropathy market report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Some of the…
Pompe Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Genzyme …
Pompe Disease emerging therapies, such as MYOZYME (alglucosidase alfa), LUMIZYME, AAV2/8-LSPhGAA, Avalglucosidase alfa, and others, are expected to boost the Pompe Disease Market in the upcoming years.
DelveInsight has launched a new report on "Pompe Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain,…
Dark Genome Therapeutics Market Deep Research Report with Forecast to 2032 | myN …
The qualitative latest Research report (2025-2032) on the Dark Genome Therapeutics Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/133611
Focused on growth…
Hodgkin's lymphoma Therapeutics Market Size Report 2032 | Affimed Therapeutics, …
DelveInsight's "Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hodgkin's Lymphoma, historical and forecasted epidemiology as well as the Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan.
Discover Key Insights into the Hodgkin's lymphoma Market with DelveInsight's In-Depth Report @ Hodgkin's lymphoma Market Size- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Hodgkin's…
CRISPR Therapies Pipeline 2024 | Intellia Therapeutics, CRISPR therapeutics, Rep …
DelveInsight's, "CRISPR Therapies Pipeline Insight 2024" report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space.
Key Takeaways from…
Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.
North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant…
